logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Josep Tabernero

Universitat Autonoma de Barcelona
H指数:146
被引数:12.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Evorpacept联合曲妥珠单抗、雷莫昔单抗和紫杉醇治疗HER2-positive胃癌: 一项随机2期试验

Nature Medicine
IF50
2026-09-240
OAAI
Kohei Shitara; Zev Wainberg; Josep Tabernero; Eric Van Cutsem; Clélia Coutzac; Christelle De La Fouchardière; Jeeyun Lee; Sun Young Rha; Yoon-Koo Kang; Philip Fanning; Alison Forgie; Cherry Mao; Daniel Brickman; Jaume Pons; Athanasios C. Tsiatis; Sophia Randolph; Keun-Wook Lee
Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial

循环肿瘤DNA指导的高风险II期和III期结肠癌辅助治疗降级或升级：PEGASUS II期试验

Nature Cancer
IF28.5
2026-09-140
OAAI
Silvia Marsoni; Clara Montagut; Filippo Pietrantonio; Andrea Sartore-Bianchi; Luca Lazzari; Francesca Bergamo; Maria Giulia Zampino; Noelia Tarazona; Mario Mandalà; Stefano Tamberi; Elena Elez; Cristina Santos Vivas; Paolo Luraghi; Michele Prisciandaro; Federica Tosi; Davide Ciardiello; Joana Vidal; Victor Seguì; Michele Palazzo; Giulia Maddalena; Katia Bencardino; Ida Taglialatela; Marta Guix; Eliana Rulli; Valentina Vettore; Federica Morano; Claudio Isella; Giovanni Crisafulli; Giorgio Patelli; Enzo Medico; Alberto Bardelli; Andrés Cervantes; Valter Torri; Josep Tabernero; Salvatore Siena; Sara Lonardi
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3

随机对照研究：比较恩考拉非尼、西妥昔单抗和FOLFIRI方案与FOLFIRI联合或不联合贝伐珠单抗治疗BRAF V600E突变型结直肠癌——BREAKWATER队列研究3组

Annals of Oncology
IF65.4
2026-05-310
OAAI
S. Kopetz; J. Tabernero; S. Lonardi; L. Shen; H.S. Wasan; T. Yoshino; E. Van Cutsem; T.W. Kim; C. Eng; F. Ciardiello; J. Desai; T.S. Maughan; R. Yaeger; T. Usari; Xiaoxi Zhang; E. Beyzarov; A. Mori; E. Whalley; Xiaosong Zhang; E. Elez
Quality and safety of research biopsies in oncology clinical trials.

肿瘤临床试验中研究活检的质量与安全。

European Journal of Cancer
IF7.1
2026-05-250
OAAI
Paolo Nuciforo; Fiorella Ruiz-Pace; José Jimenez; Raquel Comas; Roberta Fasani; Cristina Viaplana; Cesar Sevillano; Paola Martinez; Xavier Serres-Créixams; Nuria Roson; Cristina Saura; Elena Elez; Ana Oaknin; Irene Braña Garcia; Eva Muñoz-Couselo; Teresa Macarulla Mercade; Joan Carles; Josep Tabernero; Enriqueta Felip; Elena Garralda
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors

塞格图单抗阿穆纳鲁金的安全性与药代动力学、药效学及抗肿瘤活性：一项针对晚期和/或转移性实体瘤患者的I期研究

ESMO Open
IF8.3
2026-05-130
OAAI
U. Lassen; E.M.J. van Brummelen; I. Melero; E. Angevin; H. Joensuu; N.H. Segal; M. Mau-Sørensen; N. Steeghs; M.E. Rodríguez-Ruiz; K. Homicsko; J. Tabernero; M. Cañamero; D. Dejardin; C. Habigt; E. Rossmann; E. Guarin; G. Babitzki; H.E.S. Baumann; A.P. Silva; C. Adessi
Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

开发基于证据、具有成本效益的P4癌症医学，以推动在预防、治疗、患者护理方面的创新，并减少医疗不平等。

Molecular Oncology
IF4.5
2025-12-150
OAAI
Ulrik Ringborg; Joachim von Braun; Julio Celis; Anton Berns; Michael Baumann; Tit Albreht; Nancy Abou-Zeid; Vanderlei Bagnato; Christian Brandts; Chien-Jen Chen; Massimiliano di Pietro; Manjit Dosanjh; Thomas Dubois; Alexander Eggermont; Angelika Eggert; Ingemar Ernberg; Sara Faithfull; Johannes Förner; Stefan Fröhling; Manuel Heitor; Leroy Hood; Wei Jiang; Bengt Jönsson; Ravi Kannan; Maria Leptin; Su Li; Peter Lindgren; Douglas Lowy; Jun Ma; Alex Markham; Péter Nagy; Simon Oberst; M. Iqbal Parker; Danielle Rodin; Kevin Ryan; Joachim Schüz; Richard Sullivan; Josep Tabernero; Peter Turkson; Oliver Várhelyi; Harold Varmus; Chijie Wang; Elisabete Weiderpass; Nils Wilking
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

ESMO Open
IF8.3
2025-11-060
OAAI
R. Dienstmann; A. Vivancos; P. Nuciforo; S. Aguilar; F. Ruiz-Pace; C. Viaplana; J. Gonzalez; B. Fite; A. Pedrola; E. Elez; C. Saura; E. Felip; T. Macarulla; J. Capdevila; L. Fariñas-Madrid; J. Carles; J. Mateo; E. Muñoz-Cosuelo; J. Balmaña; I. Braña; E. Garralda; J. Tabernero
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Zanzalintinib联合atezolizumab与regorafenib对比治疗难治性结直肠癌(STELLAR-303)：一项随机、开放标签、III期临床试验

The Lancet
IF97.3
2025-10-200
PRE
J Randolph Hecht; Young Suk Park; Josep Tabernero; Myung-Ah Lee; Soohyeon Lee; Anna C Virgili; Marc Van den Eynde; Elisa Fontana; Marwan Fakih; Gholamreza Asghari; Jane So; Alexander Stein; Olivier Dubreuil; Lubomir Bodnar; Cixin Steven He; Guan Wang; Robina Smith; Cathy Eng; Anwaar Saeed
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效：SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

ESMO Open
IF8.3
2025-09-300
OAAI
E. Seguí; F. Brasó-Maristany; T. Pascual; E. Sanfeliu; I. Victoria; C. Saura; C. Hierro; A. López-González; Y. Izarzugaza; E. Ciruelos; J. Gavilá; F. Racca; J.M. Cejalvo; K. Amillano; L. Paz-Ares; M. Juan; E. Felip; E. Garralda; B. González; A. Arance; J. Martín-Liberal; B. Conte; B. Walbaum; A. Indacochea; O. Castillo; P. Blasco; F. Pardo; Á. Aguirre; V. Sirenko; X. González; P. Galván; A. Vivancos; J.M. Ferrero-Cafiero; A. Mulero-Sánchez; F. Salvador; G. Villacampa; R. Mesía; A. Cervantes; A. Prat; J. Tabernero
Implementation of the precision oncology program in catalonia’s public health system: results, lessons learned, and future prospects

在加泰罗尼亚公共健康体系中实施精准肿瘤学计划：结果、经验教训及未来展望

clinical translational oncology
IF0
2025-09-030
OAAI
Pilar Mur; Anna Pozuelo; Josep Tabernero; Joan Albanell; Beatriz Bellosillo; Francesc Bosch; Javier Briones; Joan Brunet; Dolors Colomer; Montserrat Domènech; Joan Manel Fontanet; Xavier Matias-Guiu; Ramon Salazar; Rosa Maria Vivanco-Hidalgo; Meritxell Mollà; Lucas Moreno; Aleix Prat; Josep Maria Ribera; Ramón Clèries; Alex Guarga; Josep A. Espinàs; Josep Maria Borras
Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Petosemtamab，一种针对表皮生长因子受体 (EGFR) 和富含亮氨酸的含G重复序列的蛋白质偶联受体 (LGR5) 的双特异性抗体，专为广泛的临床应用而设计

CANCERS
IF4.4
2025-05-140
OA
Lundberg, Ante S.; Geuijen, Cecile A. W.; Hill, Sally; Lammerts van Bueren, Jeroen J.; Fumagalli, Arianna; de Kruif, John; Silverman, Peter B.; Tabernero, Josep
A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study

BEACON研究中BRAF V600E突变型结直肠癌患者肿瘤分子变化的通俗性摘要

FUTURE ONCOLOGY
IF2.6
2025-05-090
OA
Kopetz, Scott; Murphy, Danielle A.; Pu, Jie; Ciardiello, Fortunato; Desai, Jayesh; Van Cutsem, Eric; Wasan, Harpreet Singh; Yoshino, Takayuki; Saffari, Hedieh; Zhang, Xiaosong; Hamilton, Phineas; Xie, Tao; Yaeger, Rona; Tabernero, Josep

研究方向

暂未获取到该数据
E
Eric Van Cutsem
H 指数:174论文数:1,832被引数:17.3万
É
Élena Elez
H 指数:58论文数:585被引数:1.9万
A
Andrés Cervantes
H 指数:99论文数:1,158被引数:6.1万
R
Rodrigo Dienstmann
H 指数:57论文数:651被引数:2.0万
T
Takayuki Yoshino
H 指数:88论文数:1,566被引数:4.9万
T
Teresa Macarulla
H 指数:63论文数:709被引数:2.1万
A
Ana Vivancos
H 指数:49论文数:574被引数:1.0万
P
Paolo Nucíforo
H 指数:70论文数:840被引数:1.9万
E
Elena Garralda
H 指数:46论文数:729被引数:1.0万
J
Jordi Rodón
H 指数:70论文数:1,120被引数:2.2万